RYI 250417 22.50P(RYI250417P22500) Stock Price Today

1.36
-0.74-35.24%

15min DelayClose Apr 17 16:00 ET

1.36High1.36Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Moomoo AI

Mar 22, 2024 20:46

Insider share selling, particularly below current price, is seen as negative, implying a lower price is reasonable. Modest insider ownership indicates alignment with common shareholders. The absence of insider transactions in the past three months is not encouraging.

Insiders At Ryerson Holding Sold US$1.4m In Stock, Alluding To Potential Weakness

iamiam

Mar 19, 2024 22:46

$Cleveland-Cliffs (CLF.US)$
BRING EM ALL WITH YOU
$Steel Dynamics (STLD.US)$
$United States Steel (X.US)$
$Ternium (TX.US)$
$Gerdau (GGB.US)$
$National Steel (SID.US)$
$Radius Recycling (RDUS.US)$
$Commercial Metals (CMC.US)$
$Tenaris (TS.US)$
$Ryerson (RYI.US)$
$Nucor (NUE.US)$

Moomoo AI

Nov 21, 2023 18:37

Insiders' sales of Ryerson Holding Corporation stock raise alarms as absence of purchases is worrisome. The investor sentiment remains cautious without major insider acquisitions.

Possible Bearish Signals With Ryerson Holding Insiders Disposing Stock

102054460

Nov 8, 2023 08:00

Ryerson – strong fundamentals with a margin of safety

Ryerson (NYSE: RYI) is a leading value-added processor and distributor of industrial metals with operations in the United States.
RYI's revenue growth from 2014 to 2022 was driven by changes in selling price rather than tonnage growth. The price growth, especially the price spike in the past 2 years, enabled it to generate strong earnings. But there were improvements in operating efficiencies and the company is financially sound.
It is a cycli...

Moomoo Breakfast US

May 11, 2022 20:23

Columns Today's pre-market stock movers: PTON, NIO, RBLX, U and more

Gainers:
• $Veru Inc (VERU.US)$ +25.8% (announces that in a Pre-EUA meeting held May 10 2022 FDA has agreed that the efficacy and safety data from the completed Phase 3 clinical study in hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome are sufficient to support the submission of a request for Emergency Use Authorization)
• $Desktop Metal(Delisted) (DM.US)$ +15.8% (prices offering of $100 mln of 6.0% convertible se...

RYI250417P22500

News

Comments